Evaluating the best duration for maintenance therapy in light chain amyloidosis
Official title: Evaluating Maintenance In Light chain Amyloidosis (EMILIA)
Funded at Mayo Clinic Rochester · NIH-11034184 · Data updated 2026-11-12
This study is looking at how long patients with light chain amyloidosis should continue taking daratumumab after their initial treatment to see which duration—6 months or 18 months—helps them feel better and live longer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | December 13, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $226,435 |
| NIH project number | 1R21CA288898-01A1 |
| Project ID | NIH-11034184 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with light chain amyloidosis who have shown a positive response to daratumumab-CyBorD induction therapy.
✕Less likely to help
Patients who have not been treated with daratumumab-CyBorD or those with advanced organ dysfunction may not benefit from this research.
What this research studies
This research investigates the optimal duration of maintenance therapy using daratumumab for patients with light chain amyloidosis who have responded to initial treatment. Patients who achieve a satisfactory hematological response will be randomly assigned to receive either 6 months or 18 months of daratumumab maintenance therapy. The goal is to determine which duration leads to better outcomes in terms of organ recovery and overall survival. This study aims to provide clearer guidelines for ongoing treatment in this rare condition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that enhance patient survival and quality of life in light chain amyloidosis.
How similar studies have gone: Previous studies have shown promising results with daratumumab in treating light chain amyloidosis, but this specific approach to maintenance therapy is novel.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Muchtar, Eli — Mayo Clinic Rochester
- Study coordinator: Muchtar, Eli
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney-like blood flow may cause amyloid buildup
A research project uses tiny blood-flow devices to study how certain proteins misfold and form amyloid deposits in organs like the kidney and heart.
-
Blood test to detect ATTR amyloidosis earlier using a smart detection kit
A new blood test kit aims to detect ATTR amyloidosis early using a biomarker that appears in patients but not in healthy people.
-
Detection and measurement of amyloid in people carrying the V122I TTR gene variant
This research will look for early signs of heart-related amyloidosis in people with the V122I TTR gene variant using blood tests and a special imaging scan.
-
Identifying Hidden Cardiac Amyloidosis in Black V122I TTR Carriers
This project looks for early signs of heart damage in Black individuals who carry the V122I TTR variant and may benefit from new treatments if caught early.
-
Chip phosphorylation boosts breakdown of mutant TTR to help heart amyloidosis
A scientist-led project aims to help people with a heart disease caused by a mutant protein called transthyretin (TTR) by boosting the body’s protein-cleanup systems to remove the harmful TTR deposits.
-
Finding transthyretin heart amyloid from lumbar spine surgery tissue
This project looks for transthyretin (TTR) amyloid in tissue removed during lumbar spine surgery to find people who may later develop TTR cardiac amyloidosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.